CLC BIO AND KORILOG UNVEIL KLAST SOFTWARE PLUG-IN.
The integration of the KLAST plug-in into CLC Genomics Workbench makes it possible to perform sequence similarity queries on very large data sizes, which adds significant utility to the very critical challenge in analyzing next- generation sequencing data, said Mikael Flensborg, Director of Global Partner Relations for CLC bio. This solution will allow users to significantly accelerate their research by providing them with this fast, accurate, and NGS-scalable sequence similarity search software that integrates with our CLC Genomics Workbench, and offers a very user-friendly graphical interface.
The logic of KLAST is different from BLAST, and can provide significant accelerations of seed-based heuristic comparison methods using multi-threading and SSE instructions that make the tool high-performing and more scalable than BLAST on multiple cores.
Korilog, a privately held company based in Questembert, France, is a bioinformatics company providing the next generation of graphical software to integrate and explore data on pathways, genomes and proteomes. The company provides academic and industry research labs with desktop and web-based software programs (ngKLAST) as well as expert software development services to support researchers in their R&D activities. For further information, visit http://www.korilog.com.
About CLC bio
CLC bio, a QIAGEN company based in Aarhus, Denmark, was founded in 2005 and has created commercial data analysis solutions and workbenches for next-generation sequencing (NGS). It serves leading research institutions and top pharmaceutical companies worldwide. CLC bio's products are used as an integrating workbench to handle biological data generated by a sequencer through a series of analysis stages. CLC bio's leading products are CLC Genomics Workbench, a comprehensive and user-friendly analysis package for analyzing, comparing and visualizing NGS data; and CLC Genomics Server, a flexible enterprise-level infrastructure and analysis backbone for NGS data analysis. For more information, visit http://www.clcbio.com.
QIAGEN N.V. is a Netherlands holding company publicly traded on NASDAQ and Frankfurt Prime Standard. The Company is a global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).
For more information, visit http://www.qiagen.com or call 617/765-0687.
|Printer friendly Cite/link Email Feedback|
|Publication:||GUI Program News|
|Date:||Feb 1, 2014|
|Previous Article:||ANALOG DEVICES UNVEILS NEXT GEN SIGMADSP PROCESSOR.|
|Next Article:||AISCALER SELECTS SPIRENT BLITZ.IO FOR APP TESTING.|